6. Multiplexed-PCR based next generation sequencing assay for diagnosis of bladder carcinoma in urine specimens

      Background: Urine cytology has a low sensitivity for diagnosis of high grade urothelial carcinoma. Bladder cancer harbors frequent coding mutations in TP53, FGFR3, RAS, and PIK3CA, in addition to TERT promoter mutations. The study evaluates the feasibility of a multiplexed-PCR based Next Generation sequencing (NGS) assay on urine samples for diagnosis and monitoring of bladder carcinoma.
      To read this article in full you will need to make a payment


      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect